OR WAIT null SECS
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
CTx-1301's formulation enables 3 different doses within 1 pill for ADHD.
Researchers are touting a new treatment formulated in a new delivery system that shrinks the tablet, enabling researchers to put 3 doses of CTx-1301 into the size of 1 pill.
In data presented during the American Professional Society of ADHD and Related Disorders (APSARD) 2021 Annual Conference, researchers showed the drug can be effective treating attention deficit/hyperactivity disorder (ADHD) in both high and low doses.
In an interview with HCPLive®, Matthew Brams, MD, Chief Medical Officer of Cingulate Therapeutics, and Shane Schaffer, PharmD, CEO of Cingulate, said the unique formulation could be a boost for treating ADHD over the course of a day.
Bram said most drugs on the market for ADHD work effectively, but the majority have a 8-12 hour duration. CTx-1301 contains an immediate pulse, a pulse 3 hours later, and a 20% proportion that is saved for 7 hours later.
This boost given 7 hours following taking the actual treatment limits the amount of pills needed and prevents a crash.Bram said around 60% of ADHD patients require a booster dose, but with it built right into the tablet it could drastically improve the quality of life of users.
In the phase 2 study, CTx-1301 demonstrated a statistically significant higher concentration (P <0.05) compared to Focalin XR from 9-16 hours in both low and high doses.